Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2009

01-04-2009

Decreased plasma soluble thrombomodulin levels as a risk factor for pulmonary thromboembolism

Authors: Yu-Dong Yin, Chen Wang, Zhen-Guo Zhai, Bao-Sen Pang, Yuan-Hua Yang, Xiu-Xia Huang

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2009

Login to get access

Abstract

Objective To observe the changes of the plasma soluble thrombomodulin (sTM) concentrations in patients with pulmonary thromboembolism (PTE) and assess the association between plasma sTM concentration and the risk of PTE. Patients and methods We measured plasma concentrations of sTM, protein C (PC) and protein S (PS) and examined the association between those plasma markers and the risk of PTE in 72 selected PTE patients and 70 controls. Results Significant difference was identified in plasma sTM level between overall PTE patients and controls. Female PTE patients had statistically lower sTM concentrations than male patients. A positive linear correlation was found between plasma sTM concentration and age in female patients. Decreased plasma sTM concentration was associated with a continuously and progressively increased risk for PTE in women. The concentrations of plasma PC and PS did not differ between groups and no significant quantitative association was identified between the risk of PTE and the levels of plasma PC or PS. Conclusion Decreased plasma sTM concentration is associated with an increased risk of PTE in women.
Literature
1.
Piazza G, Goldhaber SZ (2006) Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation 114(2):e28–e32PubMedCrossRef
2.
3.
Sadler JE (1997) Thrombomodulin structure and function. Thromb Haemost 78(1):392–395PubMed
4.
Owen WG, Esmon CT (1981) Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256(11):5532–5535PubMed
5.
Cadroy Y, Diquelou A, Dupouy D et al (1997) The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler Thromb Vasc Biol 17(3):520–527PubMed
6.
Lobato-Mendizabal E, Ruiz-Arguelles GJ (1990) Protein C, protein S and thrombomodulin: one of the natural antithrombotic mechanisms. Rev Invest Clin 42(1):54–62PubMed
7.
Ishii H, Majerus PW (1985) Thrombomodulin is present in human plasma and urine. J Clin Invest 76(6):2178–2181PubMedCrossRef
8.
Boffa MC, Karochkine M, Berard M (1991) Plasma thrombomodulin as a marker of endothelium damage. Nouv Rev Fr Hematol 33(6):529–530PubMed
9.
Ishii H, Uchiyama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65(5):618–623PubMed
10.
Takano S, Kimura S, Ohdama S et al (1990) Plasma thrombomodulin in health and diseases. Blood 76(10):2024–2029PubMed
11.
Salomaa V, Matei C, Aleksic N et al (1999) Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353(9166):1729–1734PubMedCrossRef
12.
Jansson JH, Boman K, Brannstrom M et al (1997) High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation 96(9):2938–2943PubMed
13.
Chan SH, Chen JH, Li YH et al (2006) Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol 111(2):280–285PubMedCrossRef
14.
Blann AD, McCollum CN (1999) von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrin 10(6):375–380CrossRef
15.
Olivot JM, Labreuche J, Aiach M et al (2004) Soluble thrombomodulin and brain infarction: case-control and prospective study. Stroke 35(8):1946–1951PubMedCrossRef
16.
Wisniewska E, Wodynska T, Kulwas A et al (2001) Thrombomodulin–endothelial thrombin receptor in blood of patients with unstable angina pectoris. Med Sci Monit 7(2):256–259PubMed
17.
Hamatake M, Ishida T, Mitsudomi T et al (1996) Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res 2(4):763–766PubMed
18.
Lager DJ, Callaghan EJ, Worth SF et al (1995) Cellular localization of thrombomodulin in human epithelium and squamous malignancies. Am J Pathol 146(4):933–943PubMed
19.
Takatori M, Iwabuchi S, Ro S et al (1999) Increased serum levels and sinusoidal expression of thrombomodulin in acute liver damage. Thromb Res 93(3):113–120PubMedCrossRef
20.
Biguzzi E, Franchi F, Bucciarelli P et al (2007) Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma. Thromb Res 120(2):289–293PubMedCrossRef
21.
Mizutani M, Yuzawa Y, Maruyama I et al (1993) Glomerular localization of thrombomodulin in human glomerulonephritis. Lab Inves 69(2):193–202
22.
Ichikawa Y, Takaya M, Shimizu H et al (1993) Thrombomodulin levels in the plasma and joint fluid from patients with rheumatoid arthritis. Tokai J Exp Clin Med 18(3–6):123–126PubMed
23.
Ho CY, Wong CK, Li EK et al (2003) Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology 42(1):117–122PubMedCrossRef
24.
Gabat S, Keller C, Kempe HP et al (1996) Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 25(3):233–241PubMed
25.
McLaren M, Elhadd TA, Greene SA et al (1999) Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 5(1):21–24PubMedCrossRef
26.
Aso Y, Fujiwara Y, Tayama K et al (2000) Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clin Chim Acta 301(1–2):135–145PubMedCrossRef
27.
Kodama S, Uchijima E, Nagai M et al (1990) One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies. Clin Chim Acta 192(3):191–199PubMedCrossRef
28.
Yamada N, Wada H, Nakase T et al (1995) Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. Blood Coagul Fibrin 6(7):627–633CrossRef
29.
Sakamaki F, Kyotani S, Nagaya N et al (2003) Increase in thrombomodulin concentrations after pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension. Chest 124(4):1305–1311PubMedCrossRef
30.
Aleksic N, Folsom AR, Cushman M et al (2003) Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study. J Thromb Haemost 1(1):88–94PubMedCrossRef
31.
Marckmann P, Nawroth P, Wahl P et al (1996) Diet, gender, and plasma thrombomodulin. Thromb Res 82(5):439–443PubMedCrossRef
32.
Liu HW, Kwong YL, Bourke C et al (1994) High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 71(4):416–419PubMed
33.
Shen MC, Lin JS, Tsay W (1997) High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. Thromb Res 87(4):377–385PubMedCrossRef
Metadata
Title
Decreased plasma soluble thrombomodulin levels as a risk factor for pulmonary thromboembolism
Authors
Yu-Dong Yin
Chen Wang
Zhen-Guo Zhai
Bao-Sen Pang
Yuan-Hua Yang
Xiu-Xia Huang
Publication date
01-04-2009
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2009
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-008-0218-x

Other articles of this Issue 3/2009

Journal of Thrombosis and Thrombolysis 3/2009 Go to the issue

OriginalPaper

Prothrombotic roles of substance-P, neurokinin-1 receptors and leukocytes in the platelet-dependent clot formation in whole blood

OriginalPaper

Early and long term outcome of rescue percutaneous coronary intervention (R-PCI): experience from a tertiary care center in Pakistan

OriginalPaper

The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura

OriginalPaper

Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years

OriginalPaper

Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists

OriginalPaper

Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits